DE1431167U - - Google Patents

Info

Publication number
DE1431167U
DE1431167U DENDAT1431167D DE1431167DU DE1431167U DE 1431167 U DE1431167 U DE 1431167U DE NDAT1431167 D DENDAT1431167 D DE NDAT1431167D DE 1431167D U DE1431167D U DE 1431167DU DE 1431167 U DE1431167 U DE 1431167U
Authority
DE
Germany
Prior art keywords
koa
üed
ïob
ättiguttbus
zzied
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DENDAT1431167D
Other languages
German (de)
English (en)
Publication of DE1431167U publication Critical patent/DE1431167U/de
Active legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DENDAT1431167D Active DE1431167U (enExample)

Publications (1)

Publication Number Publication Date
DE1431167U true DE1431167U (enExample)

Family

ID=740266

Family Applications (1)

Application Number Title Priority Date Filing Date
DENDAT1431167D Active DE1431167U (enExample)

Country Status (1)

Country Link
DE (1) DE1431167U (enExample)

Similar Documents

Publication Publication Date Title
ES2236775T3 (es) Formulacion de liberacion sostenida que contiene colageno y glocosaminoglucano.
AU777300B2 (en) Methods for treating congestive heart failure
US8916616B2 (en) Multi-functional polymeric materials and their uses
Krewson et al. Distribution of nerve growth factor following direct delivery to brain interstitium
Hoshimaru et al. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study
CA2184242C (en) Drug targeting system, method for preparing same and its use
DE69428992T2 (de) Immunologische verbesserung mit intermittierender interleukin-2 therapie
US20090035270A1 (en) COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha
DE1431167U (enExample)
DE1213032T1 (de) Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür
US11723956B2 (en) Immunomodulation after locoregional anti-tumoral treatment
WO2022119868A2 (en) Injectable biodegradable polymeric complex for glucose-responsive insulin delivery
US20230190934A1 (en) Methods and compositions for treating a tumor
KR20040052510A (ko) 림포카인 제조 및 증식성 세포 질환의 국소 조절 또는국소와 전신 조절을 위한 이의 용도
US20250152501A1 (en) Dissolving microneedle for transdermal delivery of biopharmaceutical, and manufacturing method therefor
Reddan et al. Aqueous humor from traumatized eyes triggers cell division in the epithelia of cultured lenses
Pan et al. Spinal cord injury changes cytokine transport
WO2009012443A1 (en) Nanoparticles for the elution of growth factors for recovery and regeneration of organs
AU773990B2 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
WO2020194034A1 (en) Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it
KR20140015264A (ko) 서방성 의약 조성물
Mylonas et al. 384 Rosacea-associated bacteria induce plasmacytoid dendritic cell-derived type I interferon driving flare-ups of disease
Harkins et al. 386 The genetic diversity of Staphylococcus aureus colonisation in atopic eczema disease flare
Senra et al. 385 IL-17E activates M2 macrophages to produce IL-8 in a p38 dependent manner and favor the recruitment of neutrophils in psoriatic skin
Boniface et al. 383 Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3